About
Corporate Profile
Leadership
Board of Directors
Corporate Presentation
Technology
NaV 1.7
Antiviral Combination
Diseases
CINP
Long Covid
Fibromyalgia
Pipeline
Clinical Trials
CINP 203
Investors
News
All SEC Filings
Investors
Investors
Overview
News
Press Releases
Email Alerts
Events & Presentations
Events
Presentations
Shareholder Letters
Meeting
Governance
Overview
Leadership
Board of Directors
Board Committees
Governance Documents
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Financial & Stock Info
Overview
Quote
Charts
Historical Data
Analyst Coverage
Resources
Overview
IR Contacts
FAQ
Email Alerts
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
10-K
10-K/A
10-Q
3
4
4/A
424B4
424B5
5
8-A12B
8-K
ARS
CERT
CORRESP
DEF 14A
DEFA14A
DRS
DRSLTR
EFFECT
FWP
PRE 14A
S-1
S-1/A
S-3
S-8
SC 13G
SC 13G/A
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
Date
Form
Description
PDF
XBRL
Pages
09/15/20
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
5
09/11/20
UPLOAD
SEC-generated letter
Documents
TEXT-EXTRACT
4
08/28/20
S-1
General form of registration statement for all companies including face-amount certificate companies
Documents
EX-2.1
EX-2.2
EX-3.1
EX-3.2
EX-10.1
EX-10.2
EX-10.3
EX-10.4
EX-10.5
EX-10.6
EX-10.7
EX-23.1
327
08/27/20
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
12
08/20/20
UPLOAD
SEC-generated letter
Documents
TEXT-EXTRACT
7
07/24/20
DRSLTR
Correspondence Related to Draft Registration Statement
1
07/24/20
DRS
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
174
Previous
1…
14
15
16
17
18
19
20
21
22
23
Email Alerts
Contacts
RSS News Feed